Jude Onyia Sells 2,331 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Neurocrine Biosciences Price Performance

Shares of NBIX stock traded down $0.45 during trading on Tuesday, reaching $125.44. The company’s stock had a trading volume of 751,295 shares, compared to its average volume of 873,537. The company has a market capitalization of $12.70 billion, a price-to-earnings ratio of 33.63 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The stock’s 50-day moving average price is $119.42 and its 200 day moving average price is $131.37.

Wall Street Analyst Weigh In

Several analysts have issued reports on NBIX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Royal Bank of Canada decreased their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Institutional Trading of Neurocrine Biosciences

A number of large investors have recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $30,000. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $35,000. Blue Trust Inc. lifted its position in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd grew its stake in shares of Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.